Project Report for Pharmaceutical Manufacturing
Over 50% of the world’s vaccines, 40% of generic medications in the United States, and 25% of medications used in the United Kingdom are supplied by India, a global center for pharmaceutical manufacture. Pharmaceutical production is a viable long-term business opportunity due of the robust worldwide demand. Sharda Associates prepares CA-certified, bank-ready project reports for pharmaceutical manufacturing businesses, helping you secure funding through Mudra, PMEGP, or term loans. Starting at Rs.2,999.
Get free Sample
India's Position in Global Pharma — Why This Sector Matters
India has a genuinely huge skill base of scientists, chemists, and engineers who can advance the pharmaceutical sector technically, not only in terms of volume. This talent base is the foundation of India’s pharmaceutical power. The fact that Indian pharmaceutical companies currently supply over 80% of the world’s antiretroviral drugs used in the global fight against AIDS is one indication of the importance of Indian manufacturing capabilities to global public health.
Practically speaking, this gives new business owners a big edge. India boasts a robust pharmaceutical industry with reputable manufacturers of machinery, packaging providers, API suppliers, technical experts, and regulatory knowledge. New manufacturing facilities can therefore hire skilled workers, procure raw materials more effectively, and more easily handle compliance needs. The likelihood of creating a profitable and long-lasting pharmaceutical manufacturing company is increased by this robust industrial infrastructure, which also decreases entrance barriers and operational difficulties.
Market Size and Growth Outlook
Market Segment | Value Today | Projected Value |
Domestic Pharma Industry | US$41 billion (2021) | US$65 billion by 2024; US$120–130 billion by 2030 |
Biotechnology Sector | US$64 billion (2019) | US$150 billion by 2025 |
Pharma & Medicine Exports | US$20.14 billion (FY21, till Jan) | Rising steadily year-on-year |
Within the next ten years, the pharmaceutical industry in India is predicted to almost triple, and the biotechnology sector—which includes biopharmaceuticals, bioservices, bioagriculture, bioindustry, and bioinformatics—is expanding even more quickly. A new manufacturing facility can start with generic formulations and eventually expand into specialized or biotech-related products thanks to this dual growth (conventional pharma + biotech).
Types of Pharmaceutical Manufacturing You Can Start
- Generic formulation units — tablets, capsules, syrups (most common entry point for MSMEs)
- Ayurvedic/herbal pharma units — growing demand, often simpler licensing than allopathic
- API (Active Pharmaceutical Ingredient) manufacturing — capital-intensive, higher margins
- Contract manufacturing (third-party/loan license) — manufacturing for established pharma brands under their license
- Surgical & medical consumables — bandages, syringes, IV fluids
Most first-time entrepreneurs start with generic formulation manufacturing or contract/loan license manufacturing, since it requires comparatively lower upfront investment and an established demand base, before scaling into proprietary or specialized products.
Project Cost for a Pharmaceutical Manufacturing Unit
Setup Type | Estimated Capital Cost |
Small unit (tablets/capsules, contract manufacturing) | Rs.15–40 lakh |
Mid-size formulation unit (own brand, broader product range) | Rs.40 lakh–1.5 crore |
Large unit (API manufacturing/export-oriented) | Rs.1.5 crore and above |
WHO-GMP compliant plant and machinery (mixing, granulation, tablet/capsule machines), quality control lab setup, raw material/API procurement, cleanroom and HVAC systems, packaging line, licensing and regulatory fees, and working capital for distributor credit cycles and raw material stock are important cost components.
Licenses & Compliance Required
- Drug Manufacturing License from the State Drug Controller / CDSCO (mandatory before production)
- WHO-GMP Certification — essential for credibility, institutional sales, and exports
- GST Registration (above Rs.20 lakh turnover)
- Factory License and Pollution Control Board clearance
- Loan License (if doing contract manufacturing for another brand)
- Trademark Registration (for own-brand products)
Why This Sector Offers Strong Long-Term Stability
People require medications regardless of the state of the economy, making pharmaceuticals a non-discretionary, recession-resistant product category. A well-managed pharmaceutical manufacturing facility offers far more revenue stability than most other manufacturing categories when combined with India’s position as a top global supplier and steady double-digit sector growth. However, this is only possible if licensing and quality compliance are handled correctly from the start, which is precisely where the majority of new entrepreneurs require professional advice.
How Sharda Associates Helps
With 45,500+ project reports delivered across India, we understand how to position a pharmaceutical manufacturing business for fast loan approval — whether you’re applying under Mudra, PMEGP, or a full-scale bank term loan.
Instead of using a generic template, we create your pharmaceutical manufacturing project report with accurate plant and machinery costs, raw material/working capital cycles, and licensing schedules. As required by banks, PMEGP authorities, and financial institutions, our reports include accurate DSCR, break-even analysis, ROI, and payback time calculations.
- Industry-Specific DPR covering manufacturing process, plant layout, machinery, raw materials, production capacity, and regulatory considerations.
- Government Scheme Expertise with project reports tailored for PMEGP, MUDRA, CGTMSE, Stand-Up India, and other MSME financing programs.
Starting at Rs.2,999 · 24–48 Hour Delivery · 📞 +91 89899 77769
Frequently Asked Questions
India's domestic pharmaceutical market is expected to grow from its 2021 valuation of US$41 billion to US$65 billion by 2024 and US$120–130 billion by 2030, almost tripling in just ten years.
Over half of the world's vaccines, over 40% of the US's generic drug demand, 25% of all pharmaceuticals used in the UK, and more than 80% of the world's antiretroviral drugs used to treat AIDS are supplied by India.
Generic formulation units (tablets, capsules, syrups), ayurvedic/herbal pharmaceutical units, API production, contract/loan-license manufacturing, and surgical/medical consumables are common alternatives; the simplest entry points are generic formulation and contract manufacturing.
A mid-sized own-brand formulation facility requires Rs. 40 lakh to 1.5 crore, a large API/export-oriented unit may need Rs. 1.5 crore or more, and a small contract-manufacturing plant requires Rs. 15–40 lakh.
Prior to manufacture, a Drug Manufacturing License from the State Drug Controller/CDSCO is required. Credibility in institutional sales and exports also depends on WHO-GMP certification.
Indeed. The biotechnology sector in India, which includes biopharmaceuticals, bioservices, bioagriculture, bioindustry, and bioinformatics, is expected to grow from its 2019 valuation of US$64 billion to US$150 billion by 2025.
Indeed. Larger formulation or API units normally need a structured bank term loan backed by a CA-certified project report, whereas small contract-manufacturing units usually match the Mudra Tarun or PMEGP manufacturing sector.